Agilis Biotherapeutics, Intrexon Announce Collaboration

Agilis Biotherapeutics and Intrexon Corporation

, a leader in synthetic biology, announced today an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich's ataxia (FRDA), a rare genetic neurodegenerative disease.